Day: August 14, 2023

FLORHAM PARK, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. Second Quarter and Recent Corporate HighlightsIn June, the company provided an update for its iopofosine I 131 clinical program and guidance related to its Waldenstrom’s macroglobulinemia (WM) CLOVER-WaM pivotal trial, as well as preclinical advancements to its proprietary phospholipid ether drug conjugate platform. The updates included:Top-line data from its WM CLOVER-WaM pivotal trial is expected in 2H23 and assuming NDA approval, the company remains on target for a 2024 product launch. The...

BELO HORIZONTE, Brazil, Aug. 14, 2023 (GLOBE NEWSWIRE) — Inter&Co, Inc (Inter), (NASDAQ: INTR | B3: INBR32), the premier Super App which provides financial and digital commerce services to more than 28 million customers, today reported financial results for its second quarter ended June 30, 2023. The complete earnings release has been provided on the company’s Investor Relations website at https://investors.inter.co/en/.  João Vitor Menin, CEO of Inter&Co said: “This quarter marks an inflection point in our company’s history – it was a quarter of records, with significant achievements across many fronts. We have all cylinders firing in the right direction, showcasing Inter at its best. We reported an significant combination of top- and bottom-line figures, expanding our profitability by 14x on a quarterly basis, reaching...

Second Quarter Revenue Increased 93% to $1.5 Million Second Quarter Gross Profit Increased 96% to $1.0 Million BREA, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) — Reborn Coffee, Inc. (NASDAQ: REBN) (“Reborn”, or the “Company”), a California-based retailer of specialty coffee, has reported its financial and operational results for the second quarter ended June 30, 2023. Key Financial and Operational HighlightsRevenue increased 93% to $1.5 million in Q2’23 compared to $0.8 million in Q2’22. Ended Q2’23 with 14 open locations, with four other locations in development. Company-operated store sales increased $0.7 million, or 93% in the quarter ended June 30, 2023, compared to the same period in 2022. Company-operated store gross profit was $1.0 million for the quarter ended June 30, 2023, compared to $0.5 million for...

Viactiv® Product Line Total Revenue Increased Approximately 6% for the Six Months Ended June 30, 2023, as Compared to the Six Months Ended June 30, 2022; Robust Growth in Amazon Sales Channel Demonstrates Positive Results of Company’s Focus on eCommerce Initiatives HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) — Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the three months and six months ended June 30, 2023. The Company also provided a corporate update to stockholders. Financial highlights for the three months and six months ended June 30, 2023 include the following...

WILMINGTON, Del., Aug. 14, 2023 (GLOBE NEWSWIRE) — Onfolio Holdings Inc. (NASDAQ: ONFO, ONFOW) (“Onfolio” or the “Company”), a holding company that acquires and manages a diversified portfolio of online businesses across a broad range of verticals, announces financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Financial HighlightsSecond quarter 2023 revenue grew 266% year-over-year to $1.31 million compared to $0.36 million in the second quarter of 2022 Second quarter 2023 gross profit grew 445% to $0.82 million (representing gross margin of 62.3%) vs. $0.15 million in the prior year period (representing gross margin of 41.8%) Second quarter 2023 total operating expenses increased 56% to $2.12 million vs. $1.36 million in the prior year period Second quarter 2023 net loss to common shareholders expanded...

Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on progress in key programs. . Over the last few months, Vaccinex achieved several important clinical milestones for pepinemab in both Alzheimer’s disease and Head and Neck Cancer. Alzheimer’s Disease (AD):Completed enrollment in the randomized, double-blind, Phase 1b/2...

Preliminary Second Quarter HighlightsRevenue of $272.9 million, up 2.3% year-over-year (up 2.5% on a constant currency basis) Net loss of $30.9 million Gross profit(1) of $60.9 million, up 23.0% or $11.4 million year-over-year, with a corresponding margin of 22.3% and up 3.8% year-over-year and up 1.4% sequentially Adjusted EBITDA of $40.9 million, up 12.1% year-over-year, with a corresponding margin of 15.0% and up 17.8% sequentially $106.2 million in new TCV(2) wins and renewal of $32.8M TCV reflect strength of award-winning best-in-class solutions and services Long-term Liability(3) reduced to $792 million from $1.608 billion Value enhancing initiatives include Completion of Debt Recapitalization and XBP Europe progressConference call scheduled for August 14, 2023 at 8:30 AM ET IRVING, Texas, Aug. 14, 2023 (GLOBE NEWSWIRE) —...

VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) — Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (the “Company” or “EMN”) is pleased to announce key developments during the third fiscal quarter and to date. The Company has now filed its June 30, 2023 Third Fiscal Quarter Financial Statements and Management’s Discussion and Analysis. Euro Manganese reports to a fiscal year-end of September 30. Key Developments During and Subsequent to the Quarter Chvaletice Project, Czech RepublicAward of EPCM contract to Wood for development of the Chvaletice Processing Plant. The Company selected Wood Australia as its Engineering, Procurement and Construction Management (“EPCM”) partner following a rigorous selection process. The contract has two phases, with an approval...

Record Revenue of $197.5 Million, Up 18% Year-over-Year Net loss of $6.1 million, Down 249% Year-over-Year Adjusted EBITDA (non-GAAP) of $19.8 Million, Up 54% Year-over-Year Reiterates Full Year 2023 Guidance for Revenue and Adjusted EBITDA ATLANTA, Aug. 14, 2023 (GLOBE NEWSWIRE) — Bitcoin Depot Inc. (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM operator and leading fintech company, today reported financial results for the second quarter ended June 30, 2023. Bitcoin Depot will host a conference call and webcast at 11:00 a.m. ET today. An earnings presentation and link to the webcast will be made available at ir.bitcoindepot.com. “The second quarter proved to be another quarter full of milestones for Bitcoin Depot as we delivered record revenue,” said Brandon Mintz, CEO and Founder of Bitcoin Depot. “We...